000			02208nam a2200505 i 4500
999			_c272712 _d272712
001			on1041706883
003			OCoLC
005			20180731143851.0
006			m o d f
007			cr bn||||a||||
008			180622s2018 dcu ob f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1008-I (online)
086	0		_aY 1.1/8:115-728
099			_aY 1.1/8:115-728
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce,
245	1	0	_aMedicaid Drug Review, Utilization, Good Governance Improvement Act : _breport (to accompany H.R. 5799) (including cost estimate of the Congressional Budget Office).
264		1	_a[Washington, D.C.] : _b[U.S. Government Publishing Office], _c[2018]
300			_a1 online resource (147 pages).
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
490	1		_aReport / 115th Congress, 2d session, House of Representatives ; _v115-728
500			_a"June 12, 2018."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
588			_aDescription based on online resource, PDF version; title from caption (Govinfo, viewed June 21, 2018).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. _tMedicaid Drug Review, Utilization, Good Governance Improvement Act _w(OCoLC)1041708255
810	1		_aUnited States. _bCongress. _bHouse. _tReport ; _v115-728.
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo93921
050	1	4	_aKF32 _b.E55 2018j
610	1	0	_aUnited States. _tSocial Security Act.
650		0	_aMedicare beneficiaries _xIdentification.
650		0	_aDrugs _zUnited States _xSafety measures.
650		0	_aMedicare fraud _zUnited States _xPrevention.
650		0	_aMedicaid fraud _zUnited States _xPrevention.
650		0	_aFraud _xPrevention _xGovernment policy _zUnited States.
650		0	_aOpioid abuse _xTreatment _zUnited States _xCosts.
650		0	_aMedicare _xCost control.
650		0	_aMedicare _xLaw and legislation _zUnited States.
655		7	_aLegislative materials. _2lcgft
942			_2sudocs _c8